Workflow
重大违法强制退市
icon
Search documents
21个跌停板!603388,停牌!触及强制退市!
证券时报· 2025-11-10 12:54
Core Viewpoint - *ST Yuancheng (603388) is facing the risk of "market value delisting" due to its stock closing below 500 million yuan for 20 consecutive trading days, triggering mandatory delisting indicators [3][4]. Group 1: Delisting Risk - The company announced that its stock will be suspended from trading starting November 11, 2025, pending a review by the Shanghai Stock Exchange on whether to terminate its listing [4]. - As of October 14, the company's market value was 485 million yuan, marking the first time it fell below the 500 million yuan threshold [5]. - The stock has experienced a continuous decline, with a recent price of 0.58 yuan per share and a market value of 190 million yuan, alongside 11 consecutive trading days below par value [5]. Group 2: Legal and Compliance Issues - In addition to market value delisting, *ST Yuancheng faces risks of mandatory delisting due to significant legal violations, as the China Securities Regulatory Commission issued a notice regarding false records in annual reports from 2020 to 2022 [5]. - If the subsequent administrative penalty confirms these violations, the company's stock will be terminated from listing [5]. Group 3: Financial Performance - The company has been under risk warnings and has reported a continuous decline in revenue, with a 0.1% year-on-year increase in revenue to 102 million yuan for the first three quarters of this year, while net profit remained at a loss of 143 million yuan [7]. - The company has faced three consecutive years of losses, raising concerns about its ability to continue as a going concern [6].
A股异动丨*ST长药一字跌停 股价创逾16个月新低
Ge Long Hui A P P· 2025-11-10 06:37
Core Viewpoint - *ST Changyao (300391.SZ) experienced a significant drop, hitting a limit down at 2.76 yuan, with over 650,000 sell orders, marking a new low since July 3, 2022 [2] Summary by Relevant Sections - **Company Announcement** - The company received a "Notice of Investigation" from the China Securities Regulatory Commission (CSRC) on November 7, 2025, due to suspected false reporting of financial data [2] - The CSRC has decided to initiate an investigation against the company [2] - **Potential Consequences** - If the investigation results in administrative penalties that reveal major violations, the company may face mandatory delisting due to serious misconduct [2]
*ST长药(300391)被证监会立案!或强制退市
Zheng Quan Shi Bao· 2025-11-08 00:24
Core Viewpoint - *ST Changyao has been under investigation by the China Securities Regulatory Commission (CSRC) for suspected false reporting of financial data, which could lead to a forced delisting if major violations are confirmed [2]. Financial Performance - As of December 31, 2024, *ST Changyao reported a negative net asset of 433 million yuan and an accumulated loss of 1.59 billion yuan [2]. - In the first three quarters of 2025, the company's revenue increased by 4.40% year-on-year to 105 million yuan, while the net profit attributable to shareholders decreased by 15.89% to -210 million yuan [2]. - The net profit excluding non-recurring items fell by 16.99% to -209 million yuan, with net assets further declining to -643 million yuan [2]. Stock Performance - As of November 7, *ST Changyao's stock price was 3.45 yuan per share, down 0.58%, with a total market capitalization of 1.209 billion yuan [2][3]. - The stock has shown a trading volume of 75,300 shares, with a turnover rate of 2.15% [3].
证监会鼓励“双控人”先行赔付
Core Viewpoint - The article discusses the increasing risk of mandatory delisting due to significant violations among A-share companies, highlighting the challenges investors face in protecting their rights and the need for proactive compensation measures from controlling shareholders and actual controllers of these companies [1][3][6]. Group 1: Mandatory Delisting Risks - As of November 5, 2023, 15 A-share companies have disclosed significant violation risks that could lead to mandatory delisting [2]. - *ST Yuancheng's market capitalization was reported at 218 million yuan, having been below 500 million yuan for 17 consecutive trading days, indicating a potential trigger for mandatory delisting [2]. Group 2: Investor Protection Challenges - Experts point out that investor protection in cases of mandatory delisting is hindered by the lack of compensation capability from delisted companies and insufficient legal recourse for investors [1][3]. - The China Securities Regulatory Commission (CSRC) has introduced guidelines to encourage controlling shareholders to take proactive compensation measures to mitigate investor losses [1][6]. Group 3: Proactive Compensation Measures - Proactive compensation is seen as a way to significantly enhance the efficiency of investor compensation and should be supported by a robust incentive and constraint mechanism [1][6][9]. - The CSRC's recent guidelines aim to improve the fairness and efficiency of investor protection by encouraging controlling shareholders to take responsibility for compensation [6][7]. Group 4: Legal and Institutional Recommendations - Experts recommend enhancing investor awareness and providing more efficient channels for rights protection, including collective lawsuits and proactive compensation systems [3][4]. - There is a call for a diversified investor rights protection system that includes expanding the application of proactive compensation and improving the litigation process [4][6]. Group 5: Case Studies and Practical Applications - Previous cases of proactive compensation, such as the Hai Lian Xun case, demonstrate the feasibility of establishing compensation funds by controlling shareholders [8]. - The recent initiative by Wukuang Securities to set up a proactive compensation fund for *ST Guangdao indicates a growing trend towards such measures in the market [8][9]. Group 6: Enhancing Accountability - Experts emphasize the need for a system that encourages controlling shareholders to take responsibility, linking compensation performance to market integrity and regulatory compliance [9][10]. - The establishment of a market-driven approach to compensation, allowing for various methods such as share buybacks or cash compensation, is recommended to maintain market autonomy while ensuring accountability [10].
300391,被证监会立案!或强制退市
证券时报· 2025-11-07 15:43
Core Viewpoint - *ST Changyao has been under investigation by the China Securities Regulatory Commission (CSRC) for suspected false reporting of financial data, which could lead to significant legal consequences and potential delisting if major violations are confirmed [1]. Financial Performance Summary - As of December 31, 2024, *ST Changyao reported a negative net asset of -433 million yuan and an undistributed profit of -1.59 billion yuan [1]. - For the first three quarters of 2025, the company experienced a revenue increase of 4.40% year-on-year, reaching 105 million yuan; however, the net profit attributable to shareholders decreased by 15.89% to -210 million yuan, and the non-recurring net profit fell by 16.99% to -209 million yuan [1]. - The net asset value as of the reporting period was -643 million yuan [1]. Stock Market Performance - As of November 7, *ST Changyao's stock price was 3.45 yuan per share, reflecting a decrease of 0.58%, with a total market capitalization of 1.209 billion yuan [2]. - The trading volume was 75,300 shares, with a turnover rate of 2.15% [2]. - The stock has a price-to-earnings (PE) ratio of -4.32 and a price-to-book (PB) ratio of -1.88 [2].
300391,被立案
Di Yi Cai Jing Zi Xun· 2025-11-07 13:07
Core Points - Company received a notice from the China Securities Regulatory Commission (CSRC) regarding an investigation into suspected false financial reporting [1] - The investigation is related to the company's periodic reports and financial data [1] - If the investigation leads to a determination of significant violations, the company may face mandatory delisting due to serious misconduct [1]
300391,被立案
第一财经· 2025-11-07 12:07
Group 1 - The company *ST Changyao received a notice from the China Securities Regulatory Commission (CSRC) on November 7, 2025, regarding an investigation due to suspected false reporting of financial data [1] - The CSRC has decided to initiate a case against the company, which may lead to significant legal consequences [1] - If the investigation confirms major violations, the company’s stock may face mandatory delisting due to serious legal infractions [1]
*ST长药:涉嫌财务数据虚假记载 中国证监会对公司立案
Zhi Tong Cai Jing· 2025-11-07 11:09
Core Viewpoint - The company *ST长药 (300391.SZ) has received a notice from the China Securities Regulatory Commission (CSRC) regarding an investigation into suspected false reporting of financial data, which may lead to severe penalties and potential delisting from the Shenzhen Stock Exchange if found guilty [1] Summary by Relevant Sections - **Investigation Details** - The company was notified on November 7, 2025, about the investigation due to allegations of false financial reporting [1] - The CSRC's decision to initiate the investigation is based on relevant laws and regulations [1] - **Potential Consequences** - If the CSRC confirms the allegations and determines that they constitute a major violation under the revised Shenzhen Stock Exchange listing rules (2025), the company may face mandatory delisting [1]
*ST长药(300391.SZ):涉嫌财务数据虚假记载 中国证监会对公司立案
智通财经网· 2025-11-07 10:52
Core Viewpoint - *ST Changyao (300391.SZ) has been notified by the China Securities Regulatory Commission (CSRC) regarding an investigation into alleged false reporting of financial data, which may lead to significant penalties and potential delisting from the Shenzhen Stock Exchange if found guilty [1] Summary by Relevant Sections - **Investigation Details** - The company received a "Notice of Investigation" from the CSRC on November 7, 2025, due to suspected false records in periodic financial reports [1] - **Potential Consequences** - If the CSRC confirms the violations, the company may face administrative penalties that could trigger mandatory delisting under the revised Shenzhen Stock Exchange listing rules for the Growth Enterprise Market (2025) [1]
*ST长药:因涉嫌定期报告等财务数据虚假记载被立案
Xin Lang Cai Jing· 2025-11-07 10:36
Core Viewpoint - The company, *ST Changyao, has received a notice from the China Securities Regulatory Commission (CSRC) regarding an investigation into alleged false financial reporting, which could lead to significant legal consequences and potential delisting of its stock [1] Group 1 - The company received the "Notice of Investigation" from the CSRC on November 7, 2025 [1] - The investigation is due to allegations of false records in periodic financial reports [1] - If the investigation confirms major violations, the company may face mandatory delisting due to serious legal infractions [1]